Status:
UNKNOWN
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Lead Sponsor:
Lei Li
Conditions:
Ovarian Carcinoma
Platinum-resistant Ovarian Cancer
Eligibility:
FEMALE
18-75 years
Phase:
PHASE2
Brief Summary
This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel combined with bevacizumab for platinum-resistant recurrent epithelial ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Aged 18\~75 years old
- Histologically confirmed platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
- At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
- Sufficient bone marrow function;
- Sufficient liver and renal function;
- Patients of reproductive potential were required to take effective contraceptive measures for the duration of the study and had a negative serum or urine pregnancy test result; non-lactating women;
- Patients had no disturbance of consciousness and volunteered to participate in the study.
- Exclusion Criteria
- Uncontrolled hypertension
- Tumor invading vital blood vessels
- With contraindications to chemotherapy
- With uncontrolled infection
- Patients had received anticancer therapy within 3 weeks before enrollment
- Patients were allergic or intolerant to investigational drugs or its ingredients
- Patients are not suitable for this trial as judged by investigators
Exclusion
Key Trial Info
Start Date :
March 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 27 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05310344
Start Date
March 27 2022
End Date
March 27 2024
Last Update
April 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730